A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine Insufficiency
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety of 3.0 g/day of SA-001 (to be flexibly increased or
decreased with the range from 1.5 g/day to 6.0 g/day), which will orally be administered for
52 weeks to patients with pancreatic exocrine insufficiency caused by chronic pancreatitis in
the non-compensatory stage or by pancreatectomy.